Ofatumumab in AQP4-IgG Seropositive NMOSD

This study tests a medication called ofatumumab for treating neuromyelitis optica spectrum disorder (NMOSD) — a rare autoimmune disease that attacks the optic nerves and spinal cord. NMOSD can cause episodes of vision loss and paralysis. This trial aims to see if ofatumumab can reduce these attacks. You may be eligible if: - You are 18 or older - You have been diagnosed with NMOSD with a positive AQP4-IgG antibody test - You have had at least 2 relapses in the past 24 months, with at least 1 in the past 12 months - Your disability score (EDSS) is between 0 and 7.5 - You are willing to use effective contraception if you have childbearing potential You may NOT be eligible if: - You are pregnant, breastfeeding, or planning to become pregnant - You have an active or recent serious infection (including hepatitis B or C, or tuberculosis) - You have had cancer in the past 5 years - You have had a recent live vaccine (within 6 weeks) - You are participating in another clinical trial - You have had your spleen removed Talk to your doctor to see if this trial is right for you.